ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study

 Volver  Ver
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
 ABSTRACT   06/2020
 Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib
Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib
Pivotal phase 2 study of Obinutuzumab as Monotherapy or in combination with Zanubrutinib
Pivotal phase 2 study of Obinutuzumab as Monotherapy or in combination with Zanubrutinib
 Volver